Dr. Bipasha Bose
PhD, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), India
Dr Bipasha Bose has 20 years of post-PhD research experience working in Stem Cell Biology, in academia and industry in India, Belgium and Singapore. She holds key skills in the field of clinical, as well as, R and D grade stem cells. Her noted contributions to the field of regenerative medicine involve her co-work with the scientists for deriving human embryonic stem cells (hESC) for the first time from the Indian subcontinent, differentiation of hESC into functional insulin producing β islets and their pre-clinical translation. Her present research group comprises of 6 PhD students whom she is guiding. Her hobbies include reading and practicing spirituality, nature walks, travel, painting/sketching, dance and blogging.
- Professor (Mar 2023–tilldate) – Yenepoya Research Centre, Yenepoya University, Mangaluru, Karnataka, India
- Associate Professor (Oct 2017–Mar 2023) – Yenepoya Research Centre, Yenepoya University, Mangaluru, Karnataka, India
- Assistant Professor (Oct 2014–Sept 2017) – Yenepoya Research Centre, Yenepoya University, Mangaluru, Karnataka, India
- Research Fellow and Senior Research Fellow (Nov 2009-Mar 2014) – School of Biological Sciences, Nanyang Technological University, Singapore and Singapore Institute of Clinical Science-Brener Centre for Molecular Medicine, Singapore
- Associate Academic Staff/International Mobility postdoctoral (Jan 2008-Jul 2009) – Stem Cell Institute, Catholic University Leuven, Leuven, Belgium
- Research Scientist and Senior Research Scientist (Jan 2004-Jan 2008) – Department of Regenerative Medicine, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Centre, Navi Mumbai, India
- Senior Research Fellowship, Council for Scientific and Industrial Research (CSIR), Government of India-2001-2003
- Best Poster Award, Environmental Mutagenesis Sociey of India, Kolkata, India –2003
- Photomicrograph of the Year Award, Thermo Shandon, Pittsburgh, USA –2002
- Junior Research Fellowship, Department of Atomic Energy, Government of India, –1997-2000
- Extramural Grant Awards as Principal Investigator: BRNS-DAE (48 Lakhs INR-2017-2021); SERB/DST (53 Lakh INR-2019-2022); ICMR (32 Lakhs-2022-2025)
- Best Performer of the Year-2021, under Late-Career Faculty Category (>15 years of post-PhD) from the Yenepoya Research Centre, Yenepoya (Deemed to be University)
- Training award from BIRAC, DBT, Govt of India to undergo training in the Centre for Excellence in Biopharmaceutical Technology in IIT, Delhi (Dec 10-12, 2019)
- Best Performer of the Year-2019, under Associate Professor Category from the Yenepoya Research Centre, Yenepoya (Deemed to be University)
- Top Reviewer Publons Award in 2018 and 2019 in Biochemistry and Cell Biology
- European Molecular Biology (EMBO) Travel Grant awarded to present the work/poster titled, “Stem Cells from mouse ocular surface exhibit resistance to Ultraviolet C (UCV) at low doses while high doses manifest the effects as downregulated Pax6 with concomitant upregulation of NFκβ pathway” in the EMBO workshop titled, “Molecular mechanisms of Developmental and Regenerative Biology, 11-13 November, 2018, Singapore.
- Travel Grant from Department of Biotechnology, Government of India and Wellcome Trust-DBT for participation in the Young Investigator’s Meet (YIM)-2018, Thiruvananthapuram, Kerala, IndiaDistinction in M.Sc Ag-Molecular Biology and Biotechnology, G.B.Pant University of Ag and Technology, Pantnagar, Nainital, India, 82.845%-1997
Regenerative and Cancer Stem Cells, Ocular stem cells, UV damage, Thoron inhalation, Lung stem cells, Muscle stem cells, 3D organoids, Cancer Therapeutics, Vitamin C
Dr Bose’s present focus involves differentiation of human pluripotent stem cells into functional β cells using bioactive lipids, tumor tropism of CD34+/CD45+ Hematopoeitic stem cells, effects of thoron inhalation in lung stem cells, UV induced damages in ocular surface stem cells and translational research involving cancer stem cell therapeutics using water soluble vitamins, novel Iridium, Rhenium and Ruthenium based cancer drugs and 3D organoids model.
Dr Bose’s noted contributions to the field of regenerative medicine involve her co-work with the scientists for deriving human embryonic stem cells (hESC) for the first time from the Indian subcontinent, differentiation of hESC into functional insulin producing β islets and their pre-clinical translation, differentiation of hESC into functional hepatocytes. She has also contributed in the field of adult stem cell biology and proven the myogenic potential of aged muscle stem cells and perivascular mesenchymal stem cells, hepatocyte differentiation from Multipotent Adult Progenitor cells. Her contribution in the field of basic biology of stem cells has proven the pluripotent conversion of myostatin- null muscle stem cells without using reprogramming factors. Dr. Bose also has two patents and 45 publications in PubMed indexed journal and 07 book chapters of international repute to her credit. Currently, Dr Bose is the co- In-charge of research in the Stem Cells and Regenerative Medicine Centre/Division, Yenepoya Research Centre(YRC), Yenepoya (Deemed to be University), Mangalore, India.
Her present research group comprises of 06 full time PhD students whom she is guiding and 02 PhD students have already graduated under her guideship. Moreover, her teaching responsibility also involves teaching courses in Cell and Molecular Biology and Stem Cells and Developmental Biology for Master’s students. Dr Bose is also a reviewer for reputed journals, member of internal quality assurance team of YRC and member secretary of Institutional Biosafety committee.
- Bose, B*, Nihad, M., & P, S. S. (2023). Pluripotent stem cells: Basic biology or else differentiations aimed at translational research and the role of flow cytometry. Part A: the journal of the International Society for Analytical Cytology, 103(5), 368–377. https://doi.org/10.1002/cyto.a.24726, Journal Impact Factor-4.714
- Sen, U., Shanavas, S., Nagendra, A. H., Nihad, M., Chaudhury, D., Rachamalla, H. K., Banerjee, R., Shenoy P, S*., & Bose, B*. (2023). Significance of Oct-4 transcription factor as a pivotal therapeutic target for CD44+/24– mammary tumor initiating cells: Aiming at the root of the recurrence. Cell biology international, 47(4), 742–753. https://doi.org/10.1002/cbin.11978, Journal Impact Factor-4.473
- Chaudhury, D., Sen, U., Sahoo, B. K., Bhat, N. N., Kumara K, S., Karunakara, N., Biswas, S., Shenoy P, S*., & Bose, B*. (2022). Thorium promotes lung, liver and kidney damage in BALB/c mouse via alterations in antioxidant systems. Chemico-biological interactions, 363, 109977. https://doi.org/10.1016/j.cbi.2022.109977, Journal Impact Factor-5.168
- Nagendra, A. H., Najar, M. A., Bose, B*., & Shenoy, P. S*. (2022). High concentration of sodium fluoride in drinking water induce hypertrophy versus atrophy in mouse skeletal muscle via modulation of sarcomeric proteins. Journal of hazardous materials, 432, 128654. https://doi.org/10.1016/j.jhazmat.2022.128654, Journal Impact Factor-14.224
- Bose, B*., Shenoy, S. P., Konda, S., & Wangikar, P. (2012). Human embryonic stem cell differentiation into insulin secreting β-cells for diabetes. Cell biology international, 36(11), 1013–1020. https://doi.org/10.1042/CBI20120210, Journal Impact Factor-4.714
- Assessment of cellular and molecular changes with response to thoron inhalation in mice. [36(4)/14/51/2016-BRNS, DAE, Govt of India]. (43 lakhs)
- Differentiation of human pluripotent stem cells in to functional beta islets using bio-active lipids. [EMR/2017/003114, DST- SERB, Govt. of India]. (53 lakhs)
- Skeletal muscle fluorosis; effect of fluoride on skeletal muscle cells, and its associated mechanisms in-vitro and in-vivo studies. [EMR/2017/000591 DST- SERB, Govt. of India]. (32 lakhs)
- Mandal A, Tipnis S, Ravindran G, Kulkarni J, Patki A, Ravindran G, Bose B, Kahn AF, Patki A, Khanna A, inventors; Reliance Life Sciences Pvt Ltd, assignee. Establishment of human embryonic stem cell line using mammalian cells. India, rest of Asia, Europe, Africa and United States patent WO/2007/020655. 2007, Feb 22. (Granted)
U. S. Patent
- Mandal A, Tipnis S, Ravindran G, Kulkarni J, Patki A, Pal R, Bose B, Kahn AF, Khanna A, inventors; Reliance Life Sciences Pvt Ltd, assignee. Pluripotent human embryonic stem cell line; screening a substance for its effect on a purified preparation of the stem cells; used in cell therapy and drug screening. United States patent US7811817. 2010 Oct 12. (Granted)